Exane Derivatives’s Viatris VTRS Stock Holding History

Exane Derivatives’s Portfolio VTRS Stock Details VTRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-51,742	Closed	-$563K	–	998
2022 Q1	$563K	Buy	+51,742	New	+$682K	0.16%	175
2021 Q4	–	Sell	-60,585	Closed	-$821K	–	1046
2021 Q3	$821K	Buy	60,585 +60,054	+11,310%	+$852K	0.2%	110
2021 Q2	$7.39K	Sell	531 -1,248	-70%	-$18.1K	﹤0.01%	755
2021 Q1	$24.9K	Buy	1,779 +1,314	+283%	+$21.4K	0.01%	554
2020 Q4	$8.71K	Buy	+465	New	+$7.58K	﹤0.01%	533
2020 Q3	–	Sell	-384	Closed	-$6.17K	–	774
2020 Q2	$6.17K	Hold	384	–	–	﹤0.01%	435
2020 Q1	$5.72K	Buy	+384	New	+$7.36K	﹤0.01%	449
2019 Q3	–	Sell	-6,716	Closed	-$128K	–	703
2019 Q2	$128K	Buy	6,716 +128	+2%	+$2.83K	0.02%	303
2019 Q1	$187K	Sell	6,588 -911	-12%	-$26.6K	0.04%	224
2018 Q4	$205K	Hold	7,499	–	–	0.04%	241
2018 Q3	$274K	Buy	+7,499	New	+$282K	0.05%	220
2016 Q4	–	Sell	-7	Closed	-$267	–	687
2016 Q3	$267	Buy	+7	New	+$311	﹤0.01%	505
2015 Q4	–	Sell	-426	Closed	-$17.1K	–	569
2015 Q3	$17.1K	Buy	+426	New	+$23.8K	﹤0.01%	324

Other funds holding VTRS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $23.3B AUM 26.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Exane Derivatives's VTRS Position: Q2 2022 in Review

Exane Derivatives sold out of Viatris (VTRS) in Q2 2022, closing a stake of 51,742 shares — an estimated $563K sold.

Exane Derivatives first reported a position in VTRS in Q3 2015 and held it in 13 quarters. The position peaked at $821K in Q3 2021. 1,012 funds tracked by Wall St. Rank hold VTRS as of Q2 2022.

Exane Derivatives reported no remaining Viatris position as of Q2 2022 after selling out during the quarter.
Exane Derivatives sold 51,742 Viatris shares in Q2 2022, an estimated $563K.
Exane Derivatives first reported a position in Viatris in Q3 2015 and held it in 13 quarters.
Exane Derivatives's Viatris position peaked at $821K in Q3 2021.
1,012 funds tracked by Wall St. Rank held Viatris as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.